PMID- 16621879
OWN - NLM
STAT- MEDLINE
DCOM- 20061020
LR  - 20211020
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Print)
IS  - 1355-6037 (Linking)
VI  - 92
IP  - 10
DP  - 2006 Oct
TI  - Effects of torasemide on cardiac sympathetic nerve activity and left ventricular 
      remodelling in patients with congestive heart failure.
PG  - 1434-40
AB  - OBJECTIVE: To determine the effect of torasemide, a loop diuretic with 
      antialdosteronergic properties, compared with furosemide on cardiac sympathetic 
      nerve activity in patients with congestive heart failure (CHF). METHODS: 40 
      patients with non-ischaemic CHF (left ventricular ejection fraction (LVEF) < 45%) 
      were randomly assigned to torasemide (4-8 mg/day; n = 20) or furosemide (20-40 
      mg/day; n = 20). All patients were also treated with angiotensin-converting 
      enzyme inhibitor. The delayed heart to mediastinum count (H/M) ratio, delayed 
      total defect score (TDS) and washout rate were determined from iodine-123 
      meta-iodobenzylguanidine measured before and 6 months after treatment. Left 
      ventricular end diastolic volume (LVEDV), left ventricular end systolic volume 
      (LVESV) and LVEF were also determined by echocardiography. RESULTS: After 
      treatment, in patients receiving torasemide, TDS decreased from 44 (8) to 36 (8) 
      (p < 0.001), H/M ratio increased from 1.61 (0.19) to 1.77 (0.24) (p < 0.001), and 
      washout rate decreased from 52 (12)% to 41 (14)% (p = 0.001). In addition, LVEDV 
      decreased from 173 (22) ml to 147 (30) ml (p < 0.001) and LVESV decreased from 
      117 (19) ml to 95(24) ml (p < 0.001). Although LVEF tended to increase, the 
      change was not significant (from 31 (7)% to 34 (7)%, NS). Conversely, these 
      parameters did not change significantly in patients receiving furosemide. 
      Moreover, percentage change of TDS was significantly correlated with percentage 
      change of LVEDV (r = 0.473, p < 0.05) and of LVESV (r = 0.579, p < 0.01) after 
      torasemide treatment. CONCLUSION: These findings indicate that torasemide 
      treatment can ameliorate cardiac sympathetic nerve activity and left ventricular 
      remodelling in patients with CHF.
FAU - Kasama, S
AU  - Kasama S
AD  - Department of Cardiovascular Medicine, Gunma University School of Medicine, 
      3-39-15, Showa-machi, Maebashi, Gunma 371-0034, Japan.
FAU - Toyama, T
AU  - Toyama T
FAU - Hatori, T
AU  - Hatori T
FAU - Sumino, H
AU  - Sumino H
FAU - Kumakura, H
AU  - Kumakura H
FAU - Takayama, Y
AU  - Takayama Y
FAU - Ichikawa, S
AU  - Ichikawa S
FAU - Suzuki, T
AU  - Suzuki T
FAU - Kurabayashi, M
AU  - Kurabayashi M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060418
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Diuretics)
RN  - 0 (Sulfonamides)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - W31X2H97FB (Torsemide)
SB  - IM
MH  - Aged
MH  - Autonomic Nervous System Diseases/diagnostic imaging/*drug 
      therapy/physiopathology
MH  - Diuretics/*therapeutic use
MH  - Female
MH  - Furosemide/therapeutic use
MH  - Heart Failure/diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Observer Variation
MH  - Stroke Volume/physiology
MH  - Sulfonamides/*therapeutic use
MH  - Tomography, Emission-Computed, Single-Photon
MH  - Torsemide
MH  - Ventricular Remodeling/*physiology
PMC - PMC1861038
COIS- Competing interests: None declared.
EDAT- 2006/04/20 09:00
MHDA- 2006/10/21 09:00
PMCR- 2009/10/01
CRDT- 2006/04/20 09:00
PHST- 2006/04/20 09:00 [pubmed]
PHST- 2006/10/21 09:00 [medline]
PHST- 2006/04/20 09:00 [entrez]
PHST- 2009/10/01 00:00 [pmc-release]
AID - hrt.2005.079764 [pii]
AID - ht79764 [pii]
AID - 10.1136/hrt.2005.079764 [doi]
PST - ppublish
SO  - Heart. 2006 Oct;92(10):1434-40. doi: 10.1136/hrt.2005.079764. Epub 2006 Apr 18.